Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19475014 | 1.00 | MEN1 (0.58) | MEN1TSHRKMT2ATP53SMN1; SMN2 | |
| SCHEMBL19475146 | 0.96 | MEN1 (0.53) | MEN1TSHRKMT2ATP53SMN1; SMN2 | |
| SCHEMBL19475145 | 0.96 | MEN1 (0.53) | MEN1TSHRKMT2ATP53SMN1; SMN2 | |
| SCHEMBL19505982 | 0.90 | TSHR (0.57) | MEN1TSHRKMT2ATP53ALDH1A1 | |
| SCHEMBL19505771 | 0.86 | TSHR (0.52) | MEN1TSHRKMT2ATP53ALDH1A1 | |
| SCHEMBL3855387 | 0.78 | ALDH1A1 (0.54) | MEN1TSHRKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL11640739 | 0.78 | ALDH1A1 (0.54) | MEN1TSHRKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7393837 | 0.78 | ALDH1A1 (0.60) | MEN1TSHRKMT2ATP53SMN1; SMN2 | |
| SCHEMBL19474982 | 0.76 | ALDH1A1 (0.50) | TSHRSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL19474983 | 0.76 | ALDH1A1 (0.50) | TSHRSMN1; SMN2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647671-B2 | Promysalin analogues and methods of use thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190161444-A1 | Novel Promysalin Analogues and Methods of Use Thereof | Temple University--of the Commonwealth System of Higher Education | 2019-05-30 | — | — | US | disclosed |
| WO-2017184558-A1 | NOVEL PROMYSALIN ANALOGUES AND METHODS OF USE THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184558-A1 | NOVEL PROMYSALIN ANALOGUES AND METHODS OF USE THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647671-B2 | Promysalin analogues and methods of use thereof | CCL11, MAN2A1, PREP | MEN1 443/4885TSHR 4103/4885KMT2A 1988/4885 |
| US-20190161444-A1 | Novel Promysalin Analogues and Methods of Use Thereof | MASP2, MAN2A1, CCL11 | MEN1 484/4885TSHR 4165/4885KMT2A 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.